Model‐Informed Evaluation of Drug–Drug Interaction Recommendations for Amlodipine and Nirmatrelvir‐Ritonavir: A Hypothesis‐Generating Analysis
- 14 November 2026
- journal article
- Published by Wiley in Clinical Pharmacology & Therapeutics
Abstract
While nirmatrelvir‐ritonavir effectively prevents severe COVID‐19, its ritonavir component causes significant drug–drug interactions (DDIs). Current guidelines suggest mitigating this interaction by halving the amlodipine dose or moving to every‐other‐day (EOD) dosing, then resuming the standard regimen 3–5 days post‐antiviral treatment. We applied physiologically based pharmacokinetic/pharmacodynamic (PBPK‐PD) modeling to evaluate the effects of these recommendations on systolic blood pressure (SBP) control. SARS‐CoV‐2 inpatients who received nirmatrelvir‐ritonavir (October–December 2022) and were exposed to potential DDIs were identified. An amlodipine PBPK‐PD model incorporating the diurnal variation of SBP was developed. The model was validated using amlodipine PK studies, including in DDI scenarios, while the PD model was validated against SBP data collected during amlodipine treatment. Simulations were performed in representative virtual populations, comprising various amlodipine doses and regimens, during and after nirmatrelvir‐ritonavir therapy. 362/1729 (20.9%) drugs from 166/217 (76.5%) patients were identified to have potential DDIs implicating nirmatrelvir‐ritonavir. Amlodipine was a common interacting drug (64/362, 17.7%) and often prescribed without dose adjustment (63%). Our simulations supported that continuing amlodipine during therapy may lead to SBP ≤100 mmHg at daily doses of ≥5 mg, while discontinuation may lead to SBP >130–150 mmHg. Halving the amlodipine dose during nirmatrelvir‐ritonavir treatment could provide more stable SBP control than EOD dosing. Resuming usual doses 3 days after nirmatrelvir‐ritonavir could be more important in those receiving 7.5 and 10 mg of amlodipine. DDIs between nirmatrelvir‐ritonavir and amlodipine were common. Our simulations evaluated current dose adjustment recommendations for amlodipine with mechanistic quantitative reasoning.This publication has 21 references indexed in Scilit:
- Development of a physiologically‐based pharmacokinetic model for Ritonavir characterizing exposure and drug interaction potential at both acute and steady‐state conditionsCPT: Pharmacometrics & Systems Pharmacology, 2024
- Time Course of the Interaction Between Oral Short-Term Ritonavir Therapy with Three Factor Xa Inhibitors and the Activity of CYP2D6, CYP2C19, and CYP3A4 in Healthy VolunteersClinical Pharmacokinetics, 2024
- Potential drug–drug interactions among U.S. adults treated with nirmatrelvir/ritonavir: A cross‐sectional study of the National Covid Cohort Collaborative (N3C)Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy, 2023
- Management of Drug Interactions with Inducers: Onset and Disappearance of Induction on Cytochrome P450 3A4 and Uridine Diphosphate Glucuronosyltransferase 1A1 SubstratesEuropean Journal of Drug Metabolism and Pharmacokinetics, 2023
- Recommendations for the Management of Drug–Drug Interactions Between the COVID‐19 Antiviral Nirmatrelvir/Ritonavir (Paxlovid) and ComedicationsClinical Pharmacology & Therapeutics, 2022
- Xenobiotic receptors in mediating the effect of sepsis on drug metabolismActa Pharmaceutica Sinica B, 2020
- Guiding dose adjustment of amlodipine after co-administration with ritonavir containing regimens using a physiologically-based pharmacokinetic/pharmacodynamic modelJournal of Pharmacokinetics and Pharmacodynamics, 2018
- Drug-drug interaction profile of the all-oral anti-hepatitis C virus regimen of paritaprevir/ritonavir, ombitasvir, and dasabuvirJournal of Hepatology, 2015
- Pharmacokinetic interactions between indinavir plus ritonavir and calcium channel blockersClinical Pharmacology & Therapeutics, 2005
- Pharmacodynamic modeling of the antihypertensive response to amlodipineClinical Pharmacology & Therapeutics, 1993